PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec, Inc. Launches New Z-Fish™ Antibodies - AnaSpec has announced the launch of the Z-Fish™ product line of antibodies in order to address the growing needs of the research community for zebrafish specific antibodies, peptides and other products
AnaSpec, Inc. Launches New Z-Fish™ Antibodies

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2009/05/07 - AnaSpec has announced the launch of the Z-Fish™ product line of antibodies in order to address the growing needs of the research community for zebrafish specific antibodies, peptides and other products.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Zebrafish (Danio rerio) as an experimental model has gained widespread use since the pioneering days of Dr. George Streisinger. In the year 1980, there were 18 publications, 72 in 1990, 540 in 2000 and 1159 in 2008.1 To date, there are more than 13,200 publications.2 In order to address the growing needs of the research community for zebrafish specific antibodies, peptides and other products, AnaSpec has announced the launch of the Z-Fish™ product line of antibodies.

Z-Fish™ antibodies are raised strictly from peptide antigens derived from zebrafish protein sequences, i.e. 100% zebrafish sequence homology. Leveraging AnaSpec’s expertise in peptide technology, the antigens used in raising these antibodies include non-phosphorylated and phosphorylated peptides. The antibodies are purified using proprietary purification methods.

The list of Z-Fish™ antibodies includes targets used in apoptosis and autophagy, cell cycle control, cytoskeleton, glucose and energy metabolism, signal transduction, and immunity research. Antibodies were verified in ELISA and in western blots, using zebrafish lysates. Z-Fish™ antibodies are supplied in 150 ul sizes and are enough for 15 mini gels.

Z-Fish™ cytoskeleton antibodies include anti-actin, a-smooth muscle, anti-b-actin, raised with peptide antigens either from the C or N-terminus of the protein, anti-keratin, and b-Catenin, an actin related product. b-Catenin, a protein that bridges between cadherins and actin and plays a central role in cell adhesion, can be phosphorylated by GSK-3.3-6 One phosphorylated and two non-phosphorylated antibodies are available for this protein.

References
1. ZFIN; Retrieved Apr. 15, 2009.
2. Highwire; Retrieved Apr. 15, 2009.
3. Dale, TC. Biochem. J. 329, 209 (1998).
4. Sadot, E. et al. J. Cell Sci. 115, 2771 (2002).
5. Giannini, A. et al. J. Biol. Chem. 275, 21883 (2000).
6. Thilo, H. et al. J. Biol. Chem. 277, 2330 (2002).

About AnaSpec

AnaSpec (anaspec.com) is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec, Inc. Launches New Z-Fish™ Antibodies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Ping Yang 
408-452-5055 ping[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)